Drugs / Dalcinonacog alfa
Dalcinonacog alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03995784 | Jun 2019 → Feb 2020 | hemophilia B | Catalyst Biosciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dalcinonacog alfa | “Single intravenous injection of CB2679d/Dalcinonacog alfa” NCT03995784 ↗ |
| Known as | CB2679d | “Single intravenous injection of CB2679d/Dalcinonacog alfa” NCT03995784 ↗ |
| Known as | DalcA | “Dalcinonacog alfa (DalcA), a novel subcutaneously administered recombinant human factor IX (FIX) variant” PMID 37341915 ↗ Jun 2023 |
| Modality | Protein / enzyme biologic | “Dalcinonacog alfa (DalcA), a novel subcutaneously administered recombinant human factor IX (FIX) variant” PMID 37341915 ↗ Jun 2023 |
| Route | Intravenous | “Coagulation Factor IX variant, 50 IU/kg by intravenous route” NCT03995784 ↗ |